Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83783 | 0.91 | CYP1A2 (0.50) | EPHX2EPHX1CYP1A2TDP1SMN1; SMN2 | |
| SCHEMBL3606966 | 0.83 | CA12 (0.52) | EPHX2EPHX1CYP1A2TDP1SMN1; SMN2 | |
| SCHEMBL4279033 | 0.83 | CA12 (0.52) | EPHX2EPHX1CYP1A2TDP1SMN1; SMN2 | |
| SCHEMBL20738739 | 0.83 | CA12 (0.52) | EPHX2EPHX1CYP1A2TDP1SMN1; SMN2 | |
| SCHEMBL20973712 | 0.80 | CA12 (0.39) | CA12CA1CA2CA9HTT | |
| SCHEMBL5592392 | 0.80 | CA12 (0.39) | CA12CA1CA2CA9HTT | |
| SCHEMBL524352 | 0.80 | EPHX2 (0.48) | EPHX2EPHX1CYP1A2TDP1SMN1; SMN2 | |
| SCHEMBL18825174 | 0.80 | CA12 (0.39) | CA12CA1CA2CA9HTT | |
| SCHEMBL22142324 | 0.78 | ALDH1A1 (0.48) | EPHX2EPHX1CYP1A2TDP1SMN1; SMN2 | |
| SCHEMBL22142236 | 0.78 | ALDH1A1 (0.48) | EPHX2EPHX1CYP1A2TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883776-B2 | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | claimed |
| EP-2222664-B1 | CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-29 | — | — | EP | claimed |
| EP-2222664-A1 | CYCLOALKYLOXY-AND HET ROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2010-09-01 | — | — | EP | claimed |
| WO-2009067401-A1 | CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-28 | — | — | WO | claimed |
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-21 | — | — | US | claimed |
| EP-3492451-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| CN-105712977-B | As histamine H3Cycloalkyloxypyridine compounds and heterocycloalkyloxy-pyridine compounds of receptor modulators | 詹森药业有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-10323002-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| EP-3492451-A2 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| EP-3216784-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-26 | — | — | EP | disclosed |
| US-20180022704-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | disclosed |
| US-9809547-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-07 | — | — | US | disclosed |
| US-8748596-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | disclosed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| EP-2429996-A2 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120029189-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-02 | — | — | US | disclosed |
| WO-2010107897-A2 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-23 | — | — | WO | disclosed |
| EP-2222664-A1 | CYCLOALKYLOXY-AND HET ROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009067401-A1 | CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | EPHX2 813/4885EPHX1 615/4885CYP1A2 1688/4885 |
| US-10323002-B2 | Process for the preparation of histamine H3 receptor modulators | HRH3, HRH4, HRH1 | EPHX2 440/4885EPHX1 374/4885CYP1A2 1205/4885 |
| US-20180022704-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | EPHX2 440/4885EPHX1 374/4885CYP1A2 1205/4885 |
| US-20120029189-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | EPHX2 440/4885EPHX1 374/4885CYP1A2 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.